Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EBV specific CTL: a model for immune therapy

C M Rooney1, H E Heslop, M K Brenner

  • 1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA. cmrooney@msmail.his.tch.tmc.edu

Vox Sanguinis
|August 15, 1998
PubMed
Summary

Genetically marked cytotoxic T cells (CTL) targeting Epstein-Barr virus (EBV) are safe for patients at high risk of EBV-driven lymphoma. These engineered CTL persist for years, demonstrating anti-viral and anti-tumor activity in vivo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

A Practical Guide to 16S rRNA Microbiome Analysis in Musculoskeletal Disorders.

Methods in molecular biology (Clifton, N.J.)·2023
Same author

Evidence review of physical distancing and partition screens to reduce healthcare acquired SARS-CoV-2.

Infection prevention in practice·2021
Same author

Protecting the Microbiota.

The Journal of infectious diseases·2021
Same author

Curative Radiotherapy for Lung Cancer in the UK: International Benchmarking.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

Dissemination of multiple carbapenem resistance genes in an in vitro gut model simulating the human colon.

The Journal of antimicrobial chemotherapy·2019

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Epstein-Barr virus (EBV) drives certain lymphomas, posing a risk to specific patient groups.
  • Cytotoxic T lymphocytes (CTL) are crucial for controlling viral infections and tumor surveillance.
  • Developing effective cellular therapies for EBV-associated malignancies is an ongoing challenge.

Purpose of the Study:

  • To assess the safety and persistence of genetically marked Epstein-Barr virus specific cytotoxic T cells (EBV-CTL) in patients.
  • To evaluate the in vivo anti-viral and anti-tumor efficacy of these engineered T cells.
  • To explore the potential therapeutic value of this approach for other virally-linked cancers.

Main Methods:

  • Genetically marking EBV-specific CTL using a retroviral vector for in vivo tracking.

Related Experiment Videos

  • Administering these marked EBV-CTL to 51 patients at high risk for EBV-driven lymphoma.
  • Monitoring patient safety, CTL persistence, and functional anti-viral/anti-tumor effects over time.

    • Main Results:

    • The administration of genetically marked EBV-CTL was found to be safe in the patient cohort.
    • The engineered CTL demonstrated long-term persistence, remaining detectable for several years post-infusion.
    • Evidence of both anti-viral and anti-tumor effects mediated by the persistent CTL was observed.

    Conclusions:

    • Genetically marked EBV-specific CTL represent a safe and persistent cellular therapy for high-risk patients.
    • The in vivo persistence and functional activity of these CTL support their therapeutic potential against EBV-driven malignancies.
    • Further investigation into this approach for other virally-associated cancers is warranted.